medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 5

<< Back Next >>

Med Int Mex 2021; 37 (5)

Hyperglycemia induced by corticosteroids

Ortega-Chavarría MJ, Córdova-Pluma VH, Vega-López CA, Lugo-Bautista KS, Mendoza-Sandoval AL

Language: Spanish
References: 22
Page: 759-765
PDF size: 238.53 Kb.


ABSTRACT

The variation on the glucose numbers secondary to the administration of steroids is a known and frequent adverse effect in the clinical practice, this is associated to a greater number of hospital admissions, prolonged stays, and frequent visits to the doctor. Despite this it is an undervalued situation and both the diagnosis and the treatment are not very well understood. The great variety of presentations and dosages allows the physician to prescribe these medications indiscriminately with the resulting adverse effects; the lack of clinical studies and specific recommendations for the diagnosis and treatment cause the clinical course to perpetuate; based on the mentioned background, it was decided to make this review due to the importance it represents to the clinical practice.


REFERENCES

  1. Hoes JN, Jacobs JW, Buttgereit F, Bijlsma JW. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6: 693-702. doi: 10.1038/nrrheum.2010.179.

  2. Tatsuno I, Sugiyama T. Glucocorticoid-induced diabetes mellitus is a risk for vertebral fracture during glucocorticoid treatment. Diabetes Res Clin Pract 2011; 93: e18-20. doi: 10.1016/j.diabres.2011.03.005.

  3. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid induced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17: 717-20. doi: 10.1046/j.1525-1497.2002.10649.x.

  4. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and risk for initiation of hypoglycaemic therapy. Arch Intern Med 1994; 154: 97-101.

  5. American Diabetes Association. Position statement: standards of medical care in diabetes 2009. Diabetes Care 2009; 32: S13-61. doi: 10.2337/dc09-S013.

  6. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004; 49: 139-41. doi: 10.1177/003693300404900407.

  7. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619-32. doi: 10.1111/j.1365- 2796.1994.tb00855.x.

  8. Van den Berghe G, Wouters P, Weekers F, Verwaest C, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-67. doi: 10.1056/NEJMoa011300.

  9. Saigi I, Pérez A. Manejo de la hiperglucemia inducida por corticoides. Rev Clin Esp 2010; 210(8): 397-403. doi: 10.1016/j.rce.2010.03.006.

  10. Midvedt K, Hjelmesaeth J, Hartman A, Lund K, et al. Insulin resistance after renal transplantation: the effect of steroid doce reduction and withdrawal. J Am Soc Nephrol 2004; 15: 3233-9. doi: 10.1097/01.ASN.0000145435.80005.1E.

  11. Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93. doi: 10.1111/j.1365-2362.2008.02067.x.

  12. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, et al. High-dose but not low-dose dexamethasone impairs glucosa tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996; 81: 2621-6. doi: 10.1210/jcem.81.7.8675587.

  13. Bonaventura A, Montecuco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract 2018; 139: 203- 220. doi: 10.1016/j.diabres.2018.03.006.

  14. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001; 41: 1180-94. doi: 10.1177/00912700122012733.

  15. Gustavson SM, Sandoval DA, Ertl AC, Bao S, et al. Stimulation of both type and typeII corticosteroid receptors blunts counter regulatory responses to subsequent hypoglycemia in healthyman. Am J Physiol Endocrinol Metab 2008; 294: E506-12. 14. doi: 10.1152/ajpendo.00589.2007.

  16. Pérez A, Jansen-Chaparro S, Saigi I, Bernal-López MR, et al. Glucocorticoid-induced hyperglycemia. J Diabetes 2014; 6:9-20. doi: 10.1111/1753-0407.12090.

  17. Pérez-Pérez A, Conthe Gutiérrez P, Aguilar Diosdado M, Bertomeu-Martínez V, et al. Hospital management of hyperglycemia. Med Clin (Barc) 2009; 132: 465-75. doi: 10.1016/j.medcli.2009.02.001.

  18. American Diabetes A. Erratum. Diabetes care in the hospital. Sec. 14. In standards of medical care in diabetes-2017. Diabetes Care 2017; 40 (Suppl. 1): S120-7 [Diabetes Care 2017; 40: 986]. doi: 10.2337/dc17-er07d.

  19. Van Raalte DH, Diamant M. Steroid diabetes: from mechanism to treatment? Neth J Med 2014; 72: 62-72.

  20. Clore JN, Thurby-Hay N. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15: 469-74. doi: 10.4158/ EP08331.RAR.

  21. Pérez-Pérez A, Conthe-Gutiérrez P, Aguilar-Diosdado M, Bertomeu-Martínez V, et al. Hospital management of hyperglycemia. Med Clin (Barc) 2009; 132: 465-75. doi: 10.1016/j.medcli.2009.02.001.

  22. Umpierrez CE, Smiley D, Zisman A, Prieto L, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT2 trial). Diabetes Care 2007; 30: 2181-6. doi: 10.2337/ dc07-0295.




2020     |     www.medigraphic.com